Greeting cards, gifts get greener with recycling
Americans are becoming greener, and eco-friendly products are especially relevant in the greeting card aisle. Victoria Sutton, CEO of All in The Cards, said the company has doubled production of craft recycled products for holiday 2011.
“The recycled category continues to grow for us,” she said. “Recycled cards and gift bags are on trend now. The craft look has skyrocketed for us both in the greeting card, gift bag and box categories.” Sutton said that sales on a craft recycled card have been strong when the company mixed the cards into its assortment.
“There’s increased consumer consciousness about recycled products and what that means,” said Ron Kanfi, president of NobleWorks. NobleWorks prints on demand, and can produce in-and-out spinner rack promotions containing 48 to 124 cards and as boxed Christmas card promotions.
Bill Menke, general manager of Green Paper Co., said that while customers are more informed about recycled paper, some distinctions might escape them. “In many cases, the product being produced is made from scrap from virgin pulp that has never left the mill. It’s called recycled because it’s made from scrap,” he said.
Green Paper Co.’s products, which include boxed sets of printed and blank cards, are all made from between 30% and 100% post-consumer waste. “Consumers can identify which products are made from post-consumer waste by markings on the back of the product,” Menke said.
Zacks: Warner Chilcott can withstand generic threats
NEW YORK — Drug maker Warner Chilcott’s diversified portfolio of drugs will help it weather generic challenges to its patents, according to a new report by Zacks Investment Research.
Zacks noted that Warner Chilcott recently had received a notice from Zydus Pharmaceuticals USA that the latter would seek to challenge a patent covering the ulcerative colitis drug Asacol HD in order to market a generic version by filing a regulatory approval application with the Food and Drug Administration containing a paragraph IV certification, a legal assertion that the patent is invalid, unenforceable or won’t be infringed.
The patent in question is set to expire in November 2021, though Warner Chilcott plans to sue to protect it. Zacks said other drugs made by Warner Chilcott face generic competition as well, though the firm didn’t specify which ones and took a "neutral" stance on the company.
Lilly announces senior management changes
INDIANAPOLIS — Two senior leaders at Eli Lilly are retiring, the company said Tuesday.
The Indianapolis-based drug maker announced the Dec. 31 retirements of Lilly SVP and Bio-Medicines president Bryce Carmine, and president of manufacturing operations Frank Deane. Carmine and Deane have worked at Lilly for 36 years and 33 years, respectively. Lilly USA president Dave Ricks will replace Carmine, while SVP global drug product manufacturing Maria Crowe will replace Deane.
"We’ll certainly miss Bryce and Frank and the extraordinary leadership they provided," Lilly chairman, president and CEO John Lechleiter said. "At the same time, we’re very fortunate to have talented leaders who are well prepared and ready to step into these critical roles."